SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing heightened volatility and intense community debate as investors react to the company's latest quarterly results and forward guidance, with discussions centering on its aggressive revenue growth targets for 2030 and its expanding role in AI-driven compute architectures. While bullish participants highlight the stock's long-term potential as a critical component in next-generation AI infrastructure, bears are aggressively questioning the company's valuation multiples and the sustainability of its rapid price appreciation.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors react to a quarterly report that beat revenue and user growth expectations but faced downward pressure due to cautious revenue guidance and the termination of a partnership. The community is actively debating the effectiveness of leadership and the company's long-term potential as a cash-flow-positive player in the AR and AI space.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is seeing high volatility and heavy trading volume as investors debate its upcoming earnings report, with bulls highlighting the company's massive revenue growth and expanding commercial backlog while bears focus on high cash burn and valuation concerns. The community is actively discussing whether the company's aggressive growth trajectory justifies its market cap or if the current price action is simply a pre-earnings speculative pump followed by an inevitable correction.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh stellar earnings and aggressive AI-driven ad revenue growth against broader software sector weakness and concerns over valuation. While bulls are encouraged by record-breaking margins and the potential for a massive breakout, others are focused on institutional profit-taking and fears of a long-term software overhang.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending as investors weigh significant revenue growth and a record backlog against concerns regarding ongoing equity distribution and capital structure. The community is actively debating whether the recent heavy institutional selling indicates a long-term fundamental shift or a temporary supply overhang that creates an entry opportunity ahead of future space sector momentum.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently experiencing heightened volatility and intense community debate as investors react to the completion of Rakuten's planned share sales and growing anticipation for the upcoming quarterly earnings report. While some investors are treating the recent price pullback as a strategic buying opportunity, others are expressing frustration over launch delays and questioning the company's ability to hit its aggressive 2026 satellite constellation targets.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing extreme volatility and intense community debate following a short seller report, with investors focused on the company's robust rebuttal and strong fundamentals, including recent label expansion news and high institutional interest. The prevailing community sentiment is split between 'buy-the-dip' conviction from long-term holders and caution surrounding potential near-term price manipulation.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant market volatility and intense community discussion following recent earnings and ongoing debates regarding Elevidys demand. Investors are actively contrasting the stock's discounted valuation against its commercialized gene therapy portfolio and pipeline potential, with many speculating on the impact of upcoming regulatory catalysts and potential buyout scenarios.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor bears are facing extreme pressure as a relentless melt-up in chip stocks continues to ignore valuation concerns and geopolitical risks. Community sentiment is deeply divided, with many traders frustrated by consistent after-hours rallies and a persistent disconnect between sector earnings and price action, leaving some to debate capitulation while others hold out for an expected correction.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is seeing intense market activity following an earnings report that highlighted record-breaking backlog and massive revenue growth, fueling a tug-of-war between optimistic investors citing data center demand and bearish traders focused on margin pressures. The community is actively debating whether the stock is undergoing a long-term structural re-rating driven by AI-powered infrastructure needs or if recent volatility represents an earnings-driven trap for retail shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. Vir Bio delivered incredible momentum during the...

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026...

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $10.05, for a total transaction of $221,100.00. Following the transaction, the...

Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +26.21% and +3.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-vir-biotechnology-inc-stock...

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial...

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - Here's Why

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - Here's Why...

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed following expiration of the waiting...

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane...

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000

Key Points72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026...

$VIR Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.85 up 3.41% YoY
• Reported revenue of -$0.03M down -100.96% YoY
• Vir Biotechnology expects its cash, cash equivalents and investments, including effects of the Astellas collaboration and equity financing, to fund operations into the second half of 2028.

Stocktwits

Vir Biotechnology Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.85 up 3.41% YoY
• Reported revenue of -$0.03M down -100.96% YoY
• Vir Biotechnology expects its cash, cash equivalents and investments, including effects of the Astellas collaboration and equity financing, to fund operations into the second half of 2028.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$10.29
Prev Close	$10.01
Open	$10.09
Dividend Yield	0.00%
50-Day Moving Average	$9.63
Beta	1.64
Avg. Volume	1.8M
PE Ratio	-3.16

52-Week High	$11.66
52-Week Low	$4.16
Market Capitalization	$1.61B
EPS (Annual)	-$3.16
Price to Book	1.82
Revenue Per Employee	$186,801.09

VIR
Vir Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VIR News

VIRVir Biotechnology Inc